SCHEMBL29407367

SCHEMBL29407367

CC(=O)Oc1c(Cl)cc(Cl)c(Cl)c1Sc1c(Cl)c(Cl)cc(Cl)c1OC(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.38
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
BACE1 P56817 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
HTT P42858 3/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 3/20 0.32
TSHR P16473 2/20 0.32
TOP1 P11387 1/20 0.32
PREP P48147 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31612525 0.81 ABCB11 (0.42) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL13814014 0.81 ABCB11 (0.42) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL31612522 0.81 ABCB11 (0.44) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL8666830 0.76 ABCB11 (0.50) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL4645395 0.72 ABCB11 (0.49) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL11245676 0.71 ABCB11 (0.41) ABCB11MEN1KMT2AALDH1A1RAB9A
SCHEMBL31006515 0.71 KMT2A (0.46) ABCB11MEN1KMT2AALDH1A1RAB9A
SCHEMBL5688964 0.71 LMNA (0.43) ABCB11MEN1KMT2ABACE1ALDH1A1
SCHEMBL8928647 0.70 MAPK1 (0.43) ABCB11MEN1KMT2AALDH1A1RAB9A
SCHEMBL4641540 0.69 POLB (0.43) ABCB11MEN1KMT2ABACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638748-A2 COMPOSITIONS AND METHODS FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) EDITING Intellia Therapeutics, Inc. (US) 2025-10-29 EP claimed
WO-2025038642-A1 COMPOSITIONS AND METHODS FOR GENETICALLY MODIFYING CD70 INTELLIA THERAPEUTICS, INC. (US) 2025-02-20 WO claimed
EP-4426338-A2 CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Intellia Therapeutics, Inc. (US) 2024-09-11 EP claimed
EP-4392060-A1 PROGRAMMED CELL DEATH PROTEIN 1 (PD1) COMPOSITIONS AND METHODS FOR CELL-BASED THERAPY Intellia Therapeutics, Inc. (US) 2024-07-03 EP claimed
WO-2024137766-A2 COMPOSITIONS AND METHODS FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) EDITING INTELLIA THERAPEUTICS, INC. (US) 2024-06-27 WO claimed
EP-4352225-A1 MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING Intellia Therapeutics, Inc. (US) 2024-04-17 EP claimed
EP-4288088-A2 LYMPHOCYTE ACTIVATION GENE 3 (LAG3) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Intellia Therapeutics, Inc. (US) 2023-12-13 EP claimed
EP-4288089-A2 T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM3) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Intellia Therapeutics, Inc. (US) 2023-12-13 EP claimed
EP-4288525-A1 NATURAL KILLER CELL RECEPTOR 2B4 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Intellia Therapeutics, Inc. (US) 2023-12-13 EP claimed
CN-116849291-B Fermented feed for enhancing animal immunity and preparation method thereof 广东海洋大学 2023-12-08 CN claimed
CN-116849291-A Fermented feed for enhancing animal immunity and preparation method thereof 广东海洋大学 2023-10-10 CN claimed
EP-3637235-B1 DISPLAY DEVICE SAMSUNG DISPLAY CO LTD (KR) 2023-08-30 EP claimed
CN-116590373-A Fermented lactobacillus mucilaginosus extracellular polysaccharide, preparation method and application 广东海洋大学 2023-08-15 CN claimed
WO-2023081200-A2 CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY INTELLIA THERAPEUTICS, INC. (US) 2023-05-11 WO claimed
WO-2023028471-A1 PROGRAMMED CELL DEATH PROTEIN 1 (PD1) COMPOSITIONS AND METHODS FOR CELL-BASED THERAPY INTELLIA THERAPEUTICS, INC. (US) 2023-03-02 WO claimed
WO-2022261292-A1 MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING INTELLIA THERAPEUTICS, INC. (US) 2022-12-15 WO claimed
EP-4073249-A1 MODIFIED GUIDE RNAS FOR GENE EDITING Intellia Therapeutics, Inc. (US) 2022-10-19 EP claimed
WO-2022170172-A1 NATURAL KILLER CELL RECEPTOR 2B4 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY INTELLIA THERAPEUTICS, INC. (US) 2022-08-11 WO claimed
WO-2022170193-A2 T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM3) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY INTELLIA THERAPEUTICS, INC. (US) 2022-08-11 WO claimed
WO-2022170194-A2 LYMPHOCYTE ACTIVATION GENE 3 (LAG3) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY INTELLIA THERAPEUTICS, INC. (US) 2022-08-11 WO claimed